SUBSCRIBE
SUBSCRIBE

Licensing

IN PARTNERSHIP WITH ARVINAS
Life after the lead asset: Advancing an early-stage pipeline
In this episode of Denatured presented by Arvinas, Jennifer Smith-Parker speaks to Arvinas President and CEO Randy Teel about the strategic discipline and leadership required to successfully refocus a company on an early-stage pipeline after a lead asset is outlicensed, discontinued or otherwise falls away.
July 30, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
3D Paper Cut Pair of Lung dotted with yellow tumor bacteria infection spread across on a blue background with no text. Yellow dots as virus infection in the lungs. Vector Illustration.
Business
Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail
Despite a Phase 3 miss, Gossamer Bio is full steam ahead for its lung disease asset, pointing to previous “review issues” at the FDA as one of the reasons to continue development.
July 27, 2026
 · 
3 min read
 · 
Gabrielle Masson
PRESS RELEASES
Press Releases
1cBio and Lee’s Pharmaceutical Holdings Limited Enter into Exclusive Licensing Agreement to Develop and Commercialize 1cBio’s PARP1 Inhibitor OC-3 for Oncology in Greater China and Southeast Asia
September 9, 2026
 · 
5 min read
Press Releases
Ratio Therapeutics Enters into Research Collaboration and License Agreement with RayzeBio to Advance a Novel Radiopharmaceutical Program
September 9, 2026
 · 
3 min read
Press Releases
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs
September 9, 2026
 · 
6 min read
Press Releases
Thryv Therapeutics Licenses a New Class of SGK1 Inhibitors from Spain’s CSIC and Universidad Autónoma de Madrid, Extending Its Platform into Neurodegenerative Disease
September 3, 2026
 · 
4 min read
Press Releases
Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US
September 3, 2026
 · 
3 min read
Press Releases
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim
September 2, 2026
 · 
1 min read
Press Releases
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience
September 2, 2026
 · 
4 min read
Press Releases
AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer
September 1, 2026
 · 
11 min read
Press Releases
Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
September 1, 2026
 · 
2 min read
Press Releases
Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)
August 31, 2026
 · 
6 min read
Press Releases
Leios Therapeutics Announces Exclusive Licensing Agreement and Strategic Investment with Subsidiaries of China Medical System Holdings Ltd. for 10XB-101
August 31, 2026
 · 
5 min read
Press Releases
Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays
August 26, 2026
 · 
2 min read
Press Releases
SK Biopharmaceuticals to In-License Epilepsy Drug Candidate ‘Opakalim’
August 26, 2026
 · 
15 min read
Press Releases
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
August 24, 2026
 · 
3 min read
Press Releases
Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialize YUVEZZI™ in the European Union, the United Kingdom, Switzerland, Norway, and Iceland
August 20, 2026
 · 
5 min read
Press Releases
Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint
August 10, 2026
 · 
2 min read
Press Releases
Amend Surgical Advances NanoFUSE® Bioactive Plug Development Through Exclusive Licensing Agreement with MLM Biologics
August 10, 2026
 · 
3 min read
Press Releases
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
August 10, 2026
 · 
5 min read
Press Releases
Actimed Therapeutics Reacquires Global Rights to S-oxprenolol, Broadening Pipeline Opportunity
August 6, 2026
 · 
3 min read
Press Releases
Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
August 5, 2026
 · 
8 min read